JP2019528307A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528307A5
JP2019528307A5 JP2019511664A JP2019511664A JP2019528307A5 JP 2019528307 A5 JP2019528307 A5 JP 2019528307A5 JP 2019511664 A JP2019511664 A JP 2019511664A JP 2019511664 A JP2019511664 A JP 2019511664A JP 2019528307 A5 JP2019528307 A5 JP 2019528307A5
Authority
JP
Japan
Prior art keywords
phenyl
diamine
isopropylsulfonyl
pyrimidine
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019511664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528307A (ja
JP7094566B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/048845 external-priority patent/WO2018044767A2/en
Publication of JP2019528307A publication Critical patent/JP2019528307A/ja
Publication of JP2019528307A5 publication Critical patent/JP2019528307A5/ja
Priority to JP2022096630A priority Critical patent/JP2022120151A/ja
Application granted granted Critical
Publication of JP7094566B2 publication Critical patent/JP7094566B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019511664A 2016-08-29 2017-08-28 Alk阻害剤としてのアミノピリミジン類 Active JP7094566B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022096630A JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
US62/380,818 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096630A Division JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Publications (3)

Publication Number Publication Date
JP2019528307A JP2019528307A (ja) 2019-10-10
JP2019528307A5 true JP2019528307A5 (https=) 2020-10-01
JP7094566B2 JP7094566B2 (ja) 2022-07-04

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511664A Active JP7094566B2 (ja) 2016-08-29 2017-08-28 Alk阻害剤としてのアミノピリミジン類
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022096630A Pending JP2022120151A (ja) 2016-08-29 2022-06-15 Alk阻害剤としてのアミノピリミジン類

Country Status (11)

Country Link
US (2) US10709705B2 (https=)
EP (2) EP3504203B1 (https=)
JP (2) JP7094566B2 (https=)
KR (1) KR102530871B1 (https=)
CN (2) CN109715620B (https=)
AU (2) AU2017319135B2 (https=)
IL (1) IL264638B (https=)
MX (2) MX389265B (https=)
NZ (1) NZ751713A (https=)
SG (2) SG10201914030UA (https=)
WO (1) WO2018044767A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019314625B2 (en) * 2018-07-31 2022-05-12 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
US20220117964A1 (en) * 2019-06-25 2022-04-21 Ascentage Pharma (Suzhu) Co., Ltd. Combination of fak inhibitor and btk inhibitor for treating a disease
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
CN115212311B (zh) * 2021-04-19 2024-08-09 苏州亚盛药业有限公司 一种药物组合及其用途
CA3238857A1 (en) * 2021-12-09 2023-06-15 Oncobix Co., Ltd. Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
CN116332919B (zh) * 2022-03-30 2025-08-26 苏州亚盛药业有限公司 一种alk抑制剂化合物及其中间体的制备方法
JP2026508811A (ja) 2023-01-20 2026-03-13 アセンテージ ファーマ(スーチョウ)カンパニー,リミティド Alk阻害剤またはその塩、溶媒和物の結晶形態ならびにその製造方法および使用
KR20250160958A (ko) * 2023-03-22 2025-11-14 어센테지 파마 (쑤저우) 컴퍼니 리미티드 약학적 조합 및 이의 응용
WO2025232723A1 (en) * 2024-05-06 2025-11-13 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with focal adhesion kinase inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
NZ585188A (en) 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
MXPA06003054A (es) * 2003-09-18 2006-05-31 Novartis Ag 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
RS52545B (sr) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
US8592432B2 (en) 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
BR112013008816A2 (pt) 2010-10-14 2016-06-28 Ariad Pharma Inc método de tratamento de câncer direcionado ao egfr resistente à erlotinibe ou gefitinibe, ou uso de um sal farmacêuticamente aceito em um indivíduo
MX2013008791A (es) * 2011-02-02 2013-10-07 Irm Llc Metodos para usar inhibidores de alk.
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2019528307A5 (https=)
JP2019511528A5 (https=)
JP2015533177A5 (https=)
JP2017008088A5 (https=)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
CN103402519B (zh) 肿瘤治疗剂
JP2020007311A5 (https=)
JP2019526615A5 (https=)
JP2016523974A5 (https=)
JP2017528487A5 (https=)
JP2018517686A5 (https=)
JP2018526376A5 (https=)
JP2016538313A5 (https=)
JPWO2022173678A5 (https=)
JP2015508103A5 (https=)
JP2011001339A5 (https=)
JP2016522232A5 (https=)
JP2019501195A5 (ja) 腫瘍を処置するための抗egfr組み合わせ
JP2014513110A5 (https=)
JP2015514808A5 (https=)
JP2006507271A5 (https=)
JP2015514806A5 (https=)
RU2013147744A (ru) Дозированная лекарственная форма для перорального применения
RU2014154009A (ru) Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
JP2016525076A5 (https=)